Pulmonary Hemorrhage Following Percutaneous Computed Tomography-Guided Lung Biopsy: Retrospective Review of Risk Factors, Including Aspirin Usage.
Aged
Anti-Inflammatory Agents, Non-Steroidal
/ adverse effects
Aspirin
/ adverse effects
Case-Control Studies
Hemorrhage
/ etiology
Humans
Image-Guided Biopsy
/ adverse effects
Lung
/ diagnostic imaging
Lung Diseases
/ etiology
Male
Middle Aged
Radiography, Interventional
/ methods
Retrospective Studies
Risk Factors
Tomography, X-Ray Computed
/ methods
Journal
Current problems in diagnostic radiology
ISSN: 1535-6302
Titre abrégé: Curr Probl Diagn Radiol
Pays: United States
ID NLM: 7607123
Informations de publication
Date de publication:
Historique:
received:
13
07
2018
revised:
26
10
2018
accepted:
26
10
2018
pubmed:
25
11
2018
medline:
2
6
2020
entrez:
25
11
2018
Statut:
ppublish
Résumé
To evaluate the significance of aspirin, as well as, other potential confounding risk factors, on the incidence and volume of pulmonary hemorrhage in patients undergoing percutaneous computed tomography-guided lung biopsy. This retrospective study was approved by the institutional review board. Between September 2013 and December 2014, 252 patients taking aspirin underwent transthoracic computed tomography-guided lung biopsy. Patient, technical, and lesion-related risk factors were evaluated. Univariate analysis was performed with a Student's t test, chi-square test, or Fisher's exact test, as appropriate followed by multivariate logistic regression. Of 252 patients, 49 (19.4%) continued or stopped aspirin ≤4 days prior to biopsy and 203 (80.6%) patients stopped aspirin ≥5 days prior to biopsy. Pulmonary hemorrhage occurred in 174 cases (69.0%). The median volume of hemorrhage was 3.74 cm Aspirin taken concurrently or stopped within 4 days of transthoracic lung biopsy is not an independent risk factor for pulmonary hemorrhage. The incidence of hemorrhage following lung biopsy is associated with lesion size and depth, while the severity of hemorrhage is associated with lesion size, depth, as well as traversal of intraparenchymal vessels.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the significance of aspirin, as well as, other potential confounding risk factors, on the incidence and volume of pulmonary hemorrhage in patients undergoing percutaneous computed tomography-guided lung biopsy.
METHODS
METHODS
This retrospective study was approved by the institutional review board. Between September 2013 and December 2014, 252 patients taking aspirin underwent transthoracic computed tomography-guided lung biopsy. Patient, technical, and lesion-related risk factors were evaluated. Univariate analysis was performed with a Student's t test, chi-square test, or Fisher's exact test, as appropriate followed by multivariate logistic regression.
RESULTS
RESULTS
Of 252 patients, 49 (19.4%) continued or stopped aspirin ≤4 days prior to biopsy and 203 (80.6%) patients stopped aspirin ≥5 days prior to biopsy. Pulmonary hemorrhage occurred in 174 cases (69.0%). The median volume of hemorrhage was 3.74 cm
CONCLUSION
CONCLUSIONS
Aspirin taken concurrently or stopped within 4 days of transthoracic lung biopsy is not an independent risk factor for pulmonary hemorrhage. The incidence of hemorrhage following lung biopsy is associated with lesion size and depth, while the severity of hemorrhage is associated with lesion size, depth, as well as traversal of intraparenchymal vessels.
Identifiants
pubmed: 30470549
pii: S0363-0188(18)30187-7
doi: 10.1067/j.cpradiol.2018.10.007
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12-16Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.